Investment Rating - The investment rating for the agriculture, forestry, animal husbandry, and fishery industry is "Positive" (maintained) [2] Core Insights - The agricultural industry achieved a revenue of CNY 11,498.20 billion in 2024, a year-on-year decrease of 3.68%, while the net profit attributable to shareholders rose to CNY 466.39 billion, an increase of 806.55% [6][17] - In Q1 2025, the industry reported a revenue of CNY 2,706.77 billion, a year-on-year growth of 6.79%, with a net profit of CNY 133.13 billion, up 795.07% [6][17] - The overall profitability of the industry improved significantly in Q1 2025, with gross profit margin at 12.91%, net profit margin at 5.16%, and return on equity (ROE) at 2.57%, all showing year-on-year increases [21][30] Summary by Sections Overall Industry Performance - In 2024, the agricultural industry saw a slight decline in revenue but a substantial increase in net profit, indicating improved profitability despite lower sales [17] - The profitability metrics for Q1 2025 showed significant improvements compared to the previous year, with a notable decrease in the expense ratio [21] Sub-industry Analysis - The livestock sector experienced a remarkable increase in net profit, with pig farming turning profitable in 2024 and continuing strong performance into 2025 [6][29] - The poultry farming sector also showed strong growth, with net profit increasing significantly due to reduced feed costs and improved efficiency [43][44] - The pet food sector maintained high growth rates, with revenues and profits continuing to rise [6][25] Livestock Farming - In 2024, pig farming companies generated CNY 4,370.03 billion in revenue, a slight decline, but net profit surged to CNY 320.13 billion, reflecting a recovery in profitability [29] - In Q1 2025, revenues for pig farming increased by 18.69% year-on-year, with net profit rising by 236.12% [29][30] Poultry Farming - Poultry farming companies achieved a revenue of CNY 520.71 billion in 2024, with a net profit of CNY 28.49 billion, marking a significant increase [43] - In Q1 2025, revenue continued to grow, reaching CNY 118.71 billion, with net profit increasing to CNY 4.51 billion [43][44] Feed Industry - The feed industry reported a revenue of CNY 1,863.30 billion in 2024, with a net profit of CNY 52.48 billion, showing a significant recovery in profitability [58] - In Q1 2025, revenues rose to CNY 428.66 billion, with net profit increasing to CNY 15.26 billion [58][61] Animal Health - The animal health sector saw a revenue of CNY 129.02 billion in 2024, with a net profit of CNY 10.82 billion, despite a decline in profitability [66] - In Q1 2025, revenues increased to CNY 30.96 billion, with net profit rising to CNY 4.26 billion [66]

Core Viewpoint - The company faced significant challenges in 2024 due to a deep adjustment in the breeding industry, leading to a decline in both revenue and profit, prompting a strategic shift to maintain market share [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 1.255 billion yuan, a year-on-year decrease of 21.45%, and a net profit attributable to shareholders of 109 million yuan, down 61.57% [1]. - In Q1 2025, the company reported revenue of 352 million yuan, a year-on-year increase of 1.06%, while net profit attributable to shareholders was 76 million yuan, a decrease of 27.57% [1]. Group 2: Industry Dynamics - The breeding industry is experiencing a downturn, with strong cost-cutting demands from downstream customers, leading to intensified competition in the animal health sector and a decline in product prices [1][2]. - The company’s core product, the foot-and-mouth disease vaccine, maintains a stable market share but faces pricing pressures [2]. Group 3: Product Performance - The swine vaccine segment is under pressure due to intense competition, although the company saw a significant year-on-year sales increase of 52.17% for the pig circovirus vaccine, despite facing price challenges [2]. - The ruminant vaccine segment showed resilience even in a sluggish breeding market, while the company has a competitive advantage in brucellosis prevention with a diverse product range [2]. Group 4: Research and Development - The company invested 179 million yuan in R&D in 2024, accounting for 14.25% of its revenue, achieving significant breakthroughs in non-epidemic vaccine development [3]. - The company received four new veterinary drug registration certificates and production approvals in 2024, bolstering its product pipeline for long-term growth [3]. Group 5: Earnings Forecast - The expected EPS for 2025-2027 is projected to be 0.23 yuan, 0.28 yuan, and 0.33 yuan, with corresponding dynamic PE ratios of 30, 25, and 21 times, respectively, maintaining a "hold" rating [3].

金宇生物技术股份有限公司 2024 年年度股东大会会议资料 二○二五年五月 金宇生物技术股份有限公司 2024 年年度股东大会会议资料 金宇生物技术股份有限公司 2024 年年度股东大会会议议程 会议时间：2025 年 5 月 28 日（星期三）14：00 会议地点：公司会议室 主 持 人：董事长张翀宇 | 序号 | 会议议程 | 文件号 | | --- | --- | --- | | | 主持人介绍出席会议人员到会情况及会议召开的合法有效 | | | | 性,介绍会议主要议题，宣布会议正式开始 | | | 1 | 公司 2024 年度董事会工作报告 | 文件之一 | | 2 | 公司 2024 年度监事会工作报告 | 文件之二 | | 3 | 公司 2024 年年度报告及摘要 | 文件之三 | | 4 | 公司 2024 年度财务工作报告 | 文件之四 | | 5 | 公司 2024 年度利润分配预案 | 文件之五 | | 6 | 公司 年度独立董事述职报告 2024 | 文件之六 | | 7 | 关于公司为子公司银行综合授信提供担保的议案 | 文件之七 | | 8 | 关于续聘公司 2025 年度审计机构 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-026 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内披露截至上月 末的回购进展情况。现将回购进展情况公告如下： 2025 年 4 月，公司通过上海证券交易所系统以集中竞价交易方式累计回购公 司股份 80.33 万股，占公司总股本的比例为 0.0717%，成交最高价为 7.30 元/股， 最低价为 6.79 元/股，已支付的金额为 569.78 万元（不含佣金、过户费等交易费 用）。 截至 2025 年 4 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易方 式累计回购公司股份 1,538.33 万股，占公司总股本的比例为 1.3731%，成交最高 价为 7.30 元/股，成交最低价为 6.37 元/股，支付的资金总额为 10,555.22 万元 ...

证券代码：600201 证券简称：生物股份 公告编号：2025-025 金宇生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 28 日 14 点 00 分 召开地点：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大 街 1 号公司会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 28 日 至2025 年 5 月 28 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 方式 股东大 ...

Group 1: Swine Industry - The domestic supply and demand for pigs is expected to improve marginally by Q2 2025, with pig prices supported and entering a phase of gradual upward movement. External factors such as tariff-driven increases in feed raw material prices and higher costs for imported meat are also contributing positively to pig prices. The swine sector is highlighted as a defensive asset amid macroeconomic shocks, reinforcing investment logic. Recommended stocks include Wens Foodstuff Group, Muyuan Foods, and Juxing Agriculture [4][86]. - In 2024, China's pork production is projected to reach 56.75 million tons, accounting for 49% of global production, with consumption at 57.95 million tons, representing 50% of global consumption. This positions China as the world's largest pork producer and consumer [13][15]. - The average price of pork in 2024 is estimated at 16.8 yuan per kilogram, reflecting an increase of 11.8% year-on-year. The swine farming market size is expected to reach 1.5 trillion yuan, up 11.2% year-on-year [17][32]. Group 2: Poultry Industry - The demand for white chicken remains resilient despite uncertainties from U.S.-China tariff policies and avian influenza outbreaks. The consumption of white feather broilers is expected to improve marginally, with recommended stocks including San Nong Development and He Feng Co [5][94]. - In 2024, the total output of meat chickens in China is projected to reach 14.84 billion, with white feather broilers accounting for 60.85% of this figure. The output of white feather broilers is expected to increase by 2.2% year-on-year [99]. Group 3: Animal Health - The market for piglets and poultry chicks is stable, with a solid demand for poultry chicks supported by increasing poultry farming. The market for ruminant and pet vaccines is also expected to remain robust, with recommended stocks including Bio-Group, Kexin Biology, and Pulaike [6]. Group 4: Planting and Seeds - The focus on food security is emphasized, with companies involved in high-yield genetically modified soybeans likely to benefit from the ongoing U.S.-China trade tensions. The third batch of genetically modified corn varieties is expected to be approved for planting, which may increase the area under cultivation [7]. Group 5: Feed Industry - The recovery of the swine sector is expected to boost domestic demand for feed, while overseas markets present new growth opportunities. The demand for pig feed is anticipated to rebound as pig farming profitability improves and pig stocks gradually recover [8]. Group 6: Pet Industry - The upcoming shopping festivals are expected to drive demand for pet food, with domestic brands likely to gain market share due to increased tariffs on imported high-end products. Recommended stocks include Guibao Pet, Zhongchong Co, and Petty Co [6].

金融界4月30日消息，据CDE官网沟通交流公示，于4月30日收到长春卓谊生物股份有限公司申请的"II 类会议"，当前状态"处理中"。 主要股东信息显示，长春卓谊生物股份有限公司由浙江赛尔康宁生物科技有限公司持股55.1123%、杭 州滨江创业投资有限公司持股13.4118%、宁波梅山保税港区协恒康泰投资管理合伙企业（有限合伙） 持股7.9934%、南京中钰高科一期健康产业股权投资合伙企业（有限合伙）持股7.3253%、达孜县中钰 黄山创业投资合伙企业（有限合伙）持股2.8398%。 来源：金融界 长春卓谊生物股份有限公司，成立于2005年，位于长春市，是一家以从事医药制造业为主的企业。企业 注册资本11177.9385万人民币，实缴资本11177.9385万人民币。 通过天眼查大数据分析，长春卓谊生物股份有限公司参与招投标项目414次，知识产权方面有商标信息 36条，专利信息76条，此外企业还拥有行政许可94个。 根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类 和Ⅲ类会议，就关键阶段重大问题进行沟通交流。Ⅱ类会议一般安排在申请后60日内召开，系指为药物 在研发 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688185 证券简称：康希诺 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 ■ (二)非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三)主要会计数据、财务指标发生变动的情况、原因 √适用 □不 ...

Group 1 - The core viewpoint of the news highlights a mixed performance in the livestock breeding sector, with the China Livestock Breeding Index experiencing a slight decline of 0.07% as of April 30, 2025, while specific stocks like Tiankang Biological and Tianma Technology showed gains [1] - The Agricultural and Rural Affairs Department has released an implementation plan aiming to reduce the proportion of grain used in livestock feed to 60% and soybean meal to 10% by 2030, promoting measures such as precise feed formulation and the development of high-quality forage [1] - The Livestock ETF has seen a 2.47% increase over the past month, ranking in the top quarter among comparable funds [1] Group 2 - According to a report from Guosheng Securities, the allocation of the livestock sector in fund heavy positions has significantly decreased, with a first-quarter heavy position ratio of 0.45%, down 0.06 percentage points from the previous quarter and 0.65 percentage points year-on-year, marking the lowest level in three years [2] - The current price-to-earnings ratio (PE-TTM) of the Livestock ETF is 12.89, indicating it is at a historical low, being below 98.82% of the time over the past year [2] - The China Livestock Breeding Index includes companies involved in livestock feed, veterinary drugs, and livestock farming, reflecting the overall performance of listed companies in the livestock sector [2] Group 3 - As of March 31, 2025, the top ten weighted stocks in the China Livestock Breeding Index accounted for 69.05% of the index, with Hai Da Group, Wens Foodstuffs, and Muyuan Foods being the top three [3] - The weightings of the top stocks include Hai Da Group at 11.24%, Wens Foodstuffs at 10.10%, and Muyuan Foods at 10.08%, with Tiankang Biological showing a notable increase of 2.88% [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688739 证券简称：成大生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 □适用 √ ...